Current Report Filing (8-k)
November 15 2016 - 6:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 15, 2016
JUNIPER PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-10352
|
|
59-2758596
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
33 Arch Street
Suite 3110
Boston,
Massachusetts
|
|
02110
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 639-1500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
|
Results of Operation and Financial Condition
|
On November 15, 2016, Juniper Pharmaceuticals, Inc. (the
Company), issued a press release announcing the financial results for the three-month period ending September 30, 2016, entitled Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results (the Press
Release). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in
this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18.
Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references
in such filings.
Item 9.01.
|
Financial Statements and Exhibits
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated November
15, 2016, entitled Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results, furnished herewith
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
JUNIPER PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
|
/s/ George O. Elston
|
|
|
Name:
|
|
George O. Elston
|
|
|
Title:
|
|
Chief Financial Officer
|
Date: November 15, 2016
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated November 15
, 2016, entitled Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results, furnished herewith
|
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Apr 2023 to Apr 2024